NEW YORK (GenomeWeb News) – Fluidigm today said it has closed on its public offering of 4,209,000 shares of its common stock and raised $56.1 million in net proceeds.

The South San Francisco, Calif.-based firm announced the offering last week and priced its shares at $14.25. It plans to use proceeds for R&D, commercialization efforts, working capital, and other general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.